Cytokine Release Syndrome with Relative Adrenal Insufficiency Induced by Ipilimumab and Nivolumab Combination Therapy for Clear Cell Renal Cell Carcinoma.

Autor:	Yamamoto K; Department of Respiratory Medicine, Japanese Red Cross Kyoto Daiichi Hospital, Japan., Shiotsu S; Department of Clinical Oncology, Japanese Red Cross Kyoto Daiichi Hospital, Japan., Sasakura M; Department of Respiratory Medicine, Japanese Red Cross Kyoto Daiichi Hospital, Japan., Tanaka S; Department of Respiratory Medicine, Japanese Red Cross Kyoto Daiichi Hospital, Japan., Goda S; Department of Respiratory Medicine, Japanese Red Cross Kyoto Daiichi Hospital, Japan., Tsuji T; Department of Respiratory Medicine, Japanese Red Cross Kyoto Daiichi Hospital, Japan., Yuba T; Department of Infection Control, Japanese Red Cross Kyoto Daiichi Hospital, Japan., Takumi C; Department of Clinical Oncology, Japanese Red Cross Kyoto Daiichi Hospital, Japan., Hiraoka N; Department of Respiratory Medicine, Japanese Red Cross Kyoto Daiichi Hospital, Japan.
Jazyk:	angličtina
Zdroj:	Internal medicine (Tokyo, Japan) [Intern Med] 2024 Oct 01; Vol. 63 (19), pp. 2703-2707. Date of Electronic Publication: 2024 Mar 04.
DOI:	10.2169/internalmedicine.3115-23
Abstrakt:	Combination therapy with ipilimumab and nivolumab is indicated for many types of cancers; however, several patients experience immune-related adverse events (irAEs). We herein report a case of cytokine release syndrome (CRS) in a 63-year-old woman with stage IV left clear cell renal cell carcinoma. Our patient developed CRS while taking prednisolone, 43 days after the start of ipilimumab and nivolumab administration. The patient was treated with steroid pulse therapy, which improved the symptoms of shock and respiratory failure. Increased vascular permeability and relative adrenal insufficiency are considered to be the main pathogeneses. The early administration of high-dose steroids is crucial as a replacement for corticosteroids.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu